Dublin, Jan. 14, 2019 (GLOBE NEWSWIRE) -- The "Global Xerostomia Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The xerostomia therapeutics market to grow at a CAGR of over 3% during the forecast period.

The most common disease that causes xerostomia is an inflammatory autoimmune disease. Additionally, central nervous system-related diseases including stress, depression, and anxiety can also lead to xerostomia.

Moreover, trauma to the head and neck area can alter the nerve stimuli to the mouth and impair the function to the salivary glands. Therefore, the rising incidence of the health conditions or diseases that are high-risk factors for xerostomia is expected to continue to support the growth of the global xerostomia therapeutics market during the forecast period.

Market Overview

Growing geriatric population

The increasing number of people with xerostomia is directly related to the growing geriatric population. The number of old people worldwide has been growing significantly over the years. This expected to contribute significantly to the market as this high growth in the older population helps to drive the sales of various therapeutics markets during our forecast period.

Product recalls and tedious drug approval process

Regulatory bodies have framed stringent regulations to grant marketing approval for therapeutics that are being newly developed for the treatment of xerostomia. Many applications rejected either due to the inadequate performance of the drug or because the information on the drug, which is submitted is unsatisfactory. Such stringent government regulations can lead to a delay in drug in drug approval which in turn hampers the growth of the market.

Competitive Landscape

The xerostomia therapeutics market is fragmented due to presence of many vendors in the market. The pharmaceutical companies are forming strategic collaborations which will enhance the R&D activities for new drugs for the management xerostomia.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

• Comparison by product
• OTC
• Prescription
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• Key leading countries
• Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE

PART 11: TRENDS

PART 12: VENDOR LANDSCAPE

• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors

• Colgate-Palmolive
• Daiichi Sankyo
• Eisai
• GlaxoSmithKline
• Orahealth

For more information about this report visit https://www.researchandmarkets.com/research/kf4twk/global_xerostomia?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.